耐甲氧西林金黄色葡萄球菌临床分离株在体外持续利奈唑胺胁迫下的适应进化多样性

IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES
Infection and Drug Resistance Pub Date : 2025-02-11 eCollection Date: 2025-01-01 DOI:10.2147/IDR.S493139
Tala Han, Ting Jia, Junrui Wang
{"title":"耐甲氧西林金黄色葡萄球菌临床分离株在体外持续利奈唑胺胁迫下的适应进化多样性","authors":"Tala Han, Ting Jia, Junrui Wang","doi":"10.2147/IDR.S493139","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Linezolid resistance in methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) was reported frequently in recent years, but the mechanism underlying this process was less reported, especially for clinical isolates with different genetic background. Thus, this study aims to explore the adaptive evolution characteristics underlying linezolid resistance in MRSA clinical isolates exposed to continuous induction stress of linezolid in vitro.</p><p><strong>Methods: </strong>The in vitro susceptibility of 1032 MRSA clinical isolates to linezolid was detected using commercial VITEK-2 equipment via broth microdilution. MRSA isolates with different minimum inhibitory concentration (MIC) values for linezolid were randomly selected to perform the assay of adaptive laboratory evolution with sub-inhibitory concentrations of linezolid. Polymerase chain reaction assays and sequencing techniques were performed to detect well-known molecular determinants related to linezolid resistance, including the expression of <i>optrA</i> and <i>cfr</i>, mutations of 23S rRNA gene and ribosomal protein (L3, L4, L22) encoding genes (<i>rplC, rplD, rplV</i>).</p><p><strong>Results: </strong>After induction with sequentially increasing concentrations of linezolid, all four MRSA strains (L914, L860, L1096, and L2875) evolved into linezolid-resistant strains over various induction times (480, 384, 288, and 240 h) and universally formed small colony variants. A new mutation in the domain V region of <i>23S rRNA</i> gene (C2404T) and one mutation in amino acid sequences of ribosomal protein (Met208Thr) were firstly identified among linezolid-resistant strains. Except G2576T mutations in <i>23S rRNA</i> gene, the distribution of other mutations (A2451T, T2504A, C2404T, T2500A, G2447T) exhibited obvious strain heterogeneity. Furthermore, as the MIC to linezolid increased, the copy numbers of point mutations in the V region of <i>23S rRNA</i> gene increased correspondingly.</p><p><strong>Conclusion: </strong>Strain-specific evolution of resistance to linezolid among MRSA clinical isolates was firstly identified in this study. MRSA isolates with higher MICs for linezolid evolved more easily into resistant ones, which calls for precise monitoring of linezolid resistance levels in patients receiving treatment for MRSA infections with linezolid.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"819-834"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829590/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diversity in Adaptive Evolution of Methicillin-Resistant <i>Staphylococcus aureus</i> Clinical Isolates Under Exposure to Continuous Linezolid Stress in vitro.\",\"authors\":\"Tala Han, Ting Jia, Junrui Wang\",\"doi\":\"10.2147/IDR.S493139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Linezolid resistance in methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) was reported frequently in recent years, but the mechanism underlying this process was less reported, especially for clinical isolates with different genetic background. Thus, this study aims to explore the adaptive evolution characteristics underlying linezolid resistance in MRSA clinical isolates exposed to continuous induction stress of linezolid in vitro.</p><p><strong>Methods: </strong>The in vitro susceptibility of 1032 MRSA clinical isolates to linezolid was detected using commercial VITEK-2 equipment via broth microdilution. MRSA isolates with different minimum inhibitory concentration (MIC) values for linezolid were randomly selected to perform the assay of adaptive laboratory evolution with sub-inhibitory concentrations of linezolid. Polymerase chain reaction assays and sequencing techniques were performed to detect well-known molecular determinants related to linezolid resistance, including the expression of <i>optrA</i> and <i>cfr</i>, mutations of 23S rRNA gene and ribosomal protein (L3, L4, L22) encoding genes (<i>rplC, rplD, rplV</i>).</p><p><strong>Results: </strong>After induction with sequentially increasing concentrations of linezolid, all four MRSA strains (L914, L860, L1096, and L2875) evolved into linezolid-resistant strains over various induction times (480, 384, 288, and 240 h) and universally formed small colony variants. A new mutation in the domain V region of <i>23S rRNA</i> gene (C2404T) and one mutation in amino acid sequences of ribosomal protein (Met208Thr) were firstly identified among linezolid-resistant strains. Except G2576T mutations in <i>23S rRNA</i> gene, the distribution of other mutations (A2451T, T2504A, C2404T, T2500A, G2447T) exhibited obvious strain heterogeneity. Furthermore, as the MIC to linezolid increased, the copy numbers of point mutations in the V region of <i>23S rRNA</i> gene increased correspondingly.</p><p><strong>Conclusion: </strong>Strain-specific evolution of resistance to linezolid among MRSA clinical isolates was firstly identified in this study. MRSA isolates with higher MICs for linezolid evolved more easily into resistant ones, which calls for precise monitoring of linezolid resistance levels in patients receiving treatment for MRSA infections with linezolid.</p>\",\"PeriodicalId\":13577,\"journal\":{\"name\":\"Infection and Drug Resistance\",\"volume\":\"18 \",\"pages\":\"819-834\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-02-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829590/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Drug Resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IDR.S493139\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S493139","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:近年来耐甲氧西林金黄色葡萄球菌(MRSA)对利奈唑胺耐药的报道频繁,但其机制报道较少,特别是对于具有不同遗传背景的临床分离株。因此,本研究旨在探讨体外持续诱导应激下MRSA临床分离株耐利奈唑胺的适应性进化特征。方法:采用商用VITEK-2型仪器,采用肉汤微量稀释法检测1032株MRSA临床分离株对利奈唑胺的体外敏感性。随机选取对利奈唑胺具有不同最低抑菌浓度(MIC)的MRSA分离株,进行利奈唑胺亚抑菌浓度下的适应性实验室进化实验。采用聚合酶链反应和测序技术检测与利奈唑胺耐药相关的已知分子决定因素,包括optrA和cfr的表达、23S rRNA基因的突变和核糖体蛋白(L3、L4、L22)编码基因(rplC、rplD、rplV)。结果:4株MRSA菌株(L914、L860、L1096和L2875)在不同的诱导时间(480、384、288和240 h)诱导后,均进化为耐利奈唑胺菌株,并普遍形成小菌落变异。在耐利奈唑胺菌株中首次发现23S rRNA基因V域(C2404T)和核糖体蛋白氨基酸序列(Met208Thr)突变。23S rRNA基因中除G2576T突变外,其他突变(A2451T、T2504A、C2404T、T2500A、G2447T)的分布均表现出明显的菌株异质性。此外,随着对利奈唑胺MIC的增加,23S rRNA基因V区点突变拷贝数也相应增加。结论:本研究首次发现MRSA临床分离株对利奈唑胺耐药的菌株特异性进化。对利奈唑胺mic较高的MRSA分离株更容易进化为耐药菌株,这就要求对接受利奈唑胺治疗的MRSA感染患者的利奈唑胺耐药水平进行精确监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Diversity in Adaptive Evolution of Methicillin-Resistant Staphylococcus aureus Clinical Isolates Under Exposure to Continuous Linezolid Stress in vitro.

Background: Linezolid resistance in methicillin-resistant Staphylococcus aureus (MRSA) was reported frequently in recent years, but the mechanism underlying this process was less reported, especially for clinical isolates with different genetic background. Thus, this study aims to explore the adaptive evolution characteristics underlying linezolid resistance in MRSA clinical isolates exposed to continuous induction stress of linezolid in vitro.

Methods: The in vitro susceptibility of 1032 MRSA clinical isolates to linezolid was detected using commercial VITEK-2 equipment via broth microdilution. MRSA isolates with different minimum inhibitory concentration (MIC) values for linezolid were randomly selected to perform the assay of adaptive laboratory evolution with sub-inhibitory concentrations of linezolid. Polymerase chain reaction assays and sequencing techniques were performed to detect well-known molecular determinants related to linezolid resistance, including the expression of optrA and cfr, mutations of 23S rRNA gene and ribosomal protein (L3, L4, L22) encoding genes (rplC, rplD, rplV).

Results: After induction with sequentially increasing concentrations of linezolid, all four MRSA strains (L914, L860, L1096, and L2875) evolved into linezolid-resistant strains over various induction times (480, 384, 288, and 240 h) and universally formed small colony variants. A new mutation in the domain V region of 23S rRNA gene (C2404T) and one mutation in amino acid sequences of ribosomal protein (Met208Thr) were firstly identified among linezolid-resistant strains. Except G2576T mutations in 23S rRNA gene, the distribution of other mutations (A2451T, T2504A, C2404T, T2500A, G2447T) exhibited obvious strain heterogeneity. Furthermore, as the MIC to linezolid increased, the copy numbers of point mutations in the V region of 23S rRNA gene increased correspondingly.

Conclusion: Strain-specific evolution of resistance to linezolid among MRSA clinical isolates was firstly identified in this study. MRSA isolates with higher MICs for linezolid evolved more easily into resistant ones, which calls for precise monitoring of linezolid resistance levels in patients receiving treatment for MRSA infections with linezolid.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infection and Drug Resistance
Infection and Drug Resistance Medicine-Pharmacology (medical)
CiteScore
5.60
自引率
7.70%
发文量
826
审稿时长
16 weeks
期刊介绍: About Journal Editors Peer Reviewers Articles Article Publishing Charges Aims and Scope Call For Papers ISSN: 1178-6973 Editor-in-Chief: Professor Suresh Antony An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信